Industry P pharmaphorum
Dren Bio pockets $350m for rare blood cancer programme
Dren Bio pockets $350m for rare blood cancer programme Phil.Taylor Thu, 29/10/2026 - 16:22
The latest biotech and pharma news from the trade press, updated every hour and linked straight to the publisher. Follow funding, clinical, deals and more. Every story links straight to its publisher.
Industry P pharmaphorum
Dren Bio pockets $350m for rare blood cancer programme Phil.Taylor Thu, 29/10/2026 - 16:22
Funding
European Biotechnology
Spanish biotech ALLOX has closed a €9.4 million ($10.5 million) seed round, led by Asabys with participation from Spanish and Catalan public investors, to expand its experimental biology and AI platform for targeting "difficult-to-drug" protein-protein interactions and gene-regul…
Clinical
BioPharma Dive
The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become a new treatment standard for a form of head and neck cancer.
Clinical A Applied Clinical Trials
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from an…
Clinical
Fierce Biotech
Use Kidney Genetics to Strengthen Clinical Trial Design scox Thu, 10/29/2026 - 12:04
Industry
MedTech Dive
Weeks after an investor called for leadership changes, Cooper has parted ways with its CEO and proposed a new-look board of directors.
Industry
MedTech Dive
M&A rose, but company valuations declined in the first half of 2026 compared with the year-ago period, according to EY’s Pulse of the Industry report.
Industry B BioPharm International
Lilly’s retatrutide more than doubles Ozempic’s weight loss in a phase 3 head-to-head trial, Iovance’s lifileucel reaches a 52% response rate in a biomarker-selected lung cancer subgroup, and FDA issues draft guidance on licensing individualized genome editing products.
Industry
Pharmaceutical Technology
The policy will allow licensed professionals to use certain wellness-focused peptides not approved by the FDA in their compounded medicines.
Funding P Pharmaceutical Executive
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
Industry
Clinical Trials Arena
Genmab is going to approach global agencies based on the interim Phase III data for its bispecific in first-line HNSCC. The post Genmab’s bispecific halves risk of death in first-line HNSCC appeared first on Clinical Trials Arena.
Industry
Fierce Biotech
The cost of waiting: What reaching clinical proof-of-concept sooner means for biotech cash burn scox Thu, 10/29/2026 - 11:15
Industry
Pharmaceutical Technology
Gaelic Labs is eyeing competitive benefits from its 2025 acquisition of fellow Irish beta-lactams manufacturer and further expansion.
Research
Inside Precision Medicine
A new single-cell proteomics approach has revealed distinct immune-cell protein signatures associated with oral cancer progression and lymph node involvement. The findings could pave the way for noninvasive saliva tests to help assess disease progression and identify patients at…
Agriculture
AgriBusiness Global
The global biocontrol market is projected to reach US$14.97 billion by 2032, up from an estimated US$9.83 billion in 2026,... The post Report: Global Biocontrol Market to Reach USD 15 Billion by 2032 appeared first on AgriBusiness Global.
Industry
BioPharma Dive
RFK Jr. has given notice that the agency won’t take enforcement action on six peptides that controversially won a contested recommendation from outside advisers to the FDA in July.
Industry
Pharmaceutical Technology
Abrysvo was first approved in the US in 2023 for the prevention of lower respiratory tract disease (LRTD) caused by RSV.
Industry
GEN
This eBook brings together perspectives from across the AAV development and manufacturing continuum. It explores how early commercial planning can help avoid costly delays, how standardized platform approaches and off-the-shelf plasmids can streamline development, and how next-ge…
Software A Asimov Press
Centivax is building a universal flu vaccine designed to protect against all strains of influenza—past, present, and future.
Industry
C&EN Pharmaceuticals
The institute’s scientists and engineers are rethinking the way lifesaving drugs are made
Industry P pharmaphorum
US gives $99m for Ebola jab project, as cases spread in Africa Phil.Taylor Thu, 29/10/2026 - 14:33
Industry
Fierce Pharma
Proof Over Promise: What a DTP Program Actually Looks Like When It's Working pesurya Thu, 10/29/2026 - 10:21
Regulatory
STAT Biotech
Abdul El-Sayed, the Democratic Senate candidate in Michigan, pushes back against the RFK Jr.'s claims, and the new FDA policy around peptides.
Industry B BioPharm International
DAX-044 aims to confine IL-12 activity to tumors and avoid the toxicity that has limited IL-12 therapy, with phase 1 testing expected in 2027.
Research B BioPharm International
Updated phase 2 IOV-LUN-202 data show Iovance’s TIL cell therapy lifileucel produced a 24.6% response rate in previously treated non-squamous metastatic NSCLC, rising to 52.0% in KRAS and HER2 wild-type patients, as the company launches a biomarker-enriched registrational cohort.
Regulatory B BioPharm International
The proposed FDA guidance would let sponsors add patient-specific gene editing variants to approved BLAs via in vitro data, with comments due November 27, 2026.
Industry P Pharmaceutical Commerce
In this week’s Pharma Pulse, GoodRx expands an employer offering built on manufacturer pricing for GLP-1 obesity drugs, a federal judge declines to block Lilly’s comparative Zepbound ads, and the PBM industry’s trade group turns the vertical integration debate toward drug wholesa…
Industry P PLOS Biology
by Maxwell J. Farrell, Samantha K. Tucker, Nardus Mollentze, Daniel G. Streicker A common explanation for bats being a conspicuous source of zoonotic viruses is their purported ability to coexist with viruses without suffering overt disease. Widespread acceptance of the idea that…
Industry P PLOS Biology
by Yadollah Ranjbar-Slamloo, Tsukasa Kamigaki Goal-directed behavior requires sensory information to be transformed into motor commands, yet the precise temporal structure of communication between sensory and motor cortices during this process remains poorly understood. By simult…
Research P PLOS Biology
by Eva Bons, Hélène Chabas, Hannelore MacDonald, Alejandro Escalera Ledermann, Sira Ösze, Jenny Dunstan, Nicolas Ochsner, Daniel C. Angst, Sebastian Bonhoeffer, Roland R. Regoes The study of evolution in organisms with high mutation rates requires detailed data on the genomic com…
Industry
GEN
GEN's Kevin Davies, PhD, reports from ESGCT where patient safety, expanding access to gene therapy, and progress towards an HIV vaccine were prominent themes among the early talks at ESGCT 2026. The post Hamburg Hosts 2026 European Gene Therapy Conference appeared first on GEN -…
Regulatory
STAT Biotech
Great news for peptide fans: The Trump administration is giving the peptide craze a regulatory boost, despite objections from FDA career scientists.
Industry P pharmaphorum
Lilly's tirzepatide juggernaut is still gathering momentum Phil.Taylor Thu, 29/10/2026 - 13:39
Regulatory
MedTech Dive
The first-of-its-kind transcatheter device treats paravalvular leak after valve replacement surgery, to spare the patient from another open-heart surgery.
Clinical
MedCity News
Scientific progress only really matters if it changes what life looks like for those living with OCD. That’s because for someone who has spent years losing hours to their obsessions and compulsions, meaningful progress should mean a significant change in their lives. The post Bey…
Industry
STAT Biotech
Ahead of its FDA approval decision on Nov 30, Vertex's kidney disease drug is being heavily scrutinized for infection risk.
Clinical B BioPharm International
In the 80-week phase 3 TRANSCEND-T2D-2 trial in adults with type 2 diabetes, Eli Lilly’s GIP/GLP-1/glucagon triple agonist retatrutide lowered A1C by 2.2% and body weight by up to 20.9%, compared with 1.8% and 9.4% with Ozempic 2 mg.
Manufacturing P Pharmaceutical Commerce
Why outdated paper prescribing information is creating unnecessary cost, complexity and friction across a modern pharmaceutical supply chain.
Industry
PharmaVoice
As the industry donates and lobbies in both political directions, ongoing drug policy issues and a new head of PhRMA could complicate its traditional campaign playbook.